RhPSMA-7.3(18F)-PET Scan to Detect Prostate Cancer in Patients with Early PSA Recurrence
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Flotufolastat F-18, sold under the brand name Posluma, is a radioactive diagnostic agent for use with positron emission tomography (PET) imaging for prostate cancer. The research is being done to study the capability of 18F-rhPSMA-7.3 (flotufolastat F-18) PET scan to detect prostate cancer when there are very low levels of Prostate-Specific Antigen (PSA) following previous radical prostatectomy surgery.
Eligibility
Participation Requirements
Sex: Male
Minimum Age: 18
Healthy Volunteers: f
View:
• History of localized adenocarcinoma of the prostate with prior curative intent radical prostatectomy.
• An elevated PSA test result that is greater than or equal to 0.1 ng/ml and less than 0.5
Locations
United States
Florida
AdventHealth
RECRUITING
Orlando
Contact Information
Primary
AdventHealth AdventHealth Oncology Research
CFD.ResearchOncology@AdventHealth.com
407-303-2090
Time Frame
Start Date: 2024-09-20
Estimated Completion Date: 2027-10-10
Participants
Target number of participants: 30
Treatments
Other: Open Label Main Arm
Single Arm receiving PET scan with 18F-rhPSMA-7.3 (Posluma)
Related Therapeutic Areas
Sponsors
Leads: AdventHealth
Collaborators: Blue Earth Diagnostics